Biotech building facility to make genome-edited, off-the-shelf CAR-T therapies

Precision BioSciences, one of the biotechs working with so-called off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, last year bagged $110 million in a series B round. Some of that cash has gone toward building out a manufacturing facility at its Durham, North Carolina, headquarters it says will be up and running by the end of the year.